Impact News +++ Corcept Therapeutics: Aktie stürzt nach verlorener Patent-Berufung ab (Investing.com DE) +++ CORCEPT THERAPEUTICS Aktie +5,60%

UNIQURE Aktie

>UNIQURE Aktienkurs

20.4 EUR +2.5% (TradegateBSX)

Ask: 20.35 EUR / 990 Stück

Bid: 20.17 EUR / 1000 Stück

Tagesumsatz: 4703 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

UNIQURE Aktie über LYNX handeln

Intraday

1 Jahr

>UNIQURE Performance

1 Woche: -0,4%

1 Monat: +2,6%

3 Monate: -19,7%

6 Monate: +53,2%

1 Jahr: +52,8%

laufendes Jahr: -3,1%

>UNIQURE Aktie

Name:

UNIQURE N.V. EO -,05

Land:

Niederlande

Sektor:

Gesundheit

ISIN/ Wkn:

NL0010696654 / A1XDTV

Symbol/ Ticker:

UQ1 (Frankfurt) / QURE (NASDAQ)

Kürzel:

FRA:UQ1, ETR:UQ1, UQ1:GR, NASDAQ:QURE

Index:

Webseite:

https://www.uniqure.com/

Profil:

uniQure N.V. is a biopharmaceutical company specializing in the development of gene therapies for patients with severe genetic and other devastating diseases. Its primary focus lies in leveraging aden..
>Volltext..

Marktkapitalisierung:

1067.35 Mio. EUR

Unternehmenswert:

928.59 Mio. EUR

Umsatz:

13.31 Mio. EUR

EBITDA:

-149.52 Mio. EUR

Nettogewinn:

-198.74 Mio. EUR

Gewinn je Aktie:

-3.71 EUR

Schulden:

449.34 Mio. EUR

Liquide Mittel:

504.61 Mio. EUR

Operativer Cashflow:

-130.13 Mio. EUR

Bargeldquote:

6.9

Umsatzwachstum:

-47.72%

Gewinnwachstum:

6.84%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

UNIQURE

Letzte Datenerhebung:

19.02.26

>UNIQURE Kennzahlen

Aktien/ Unternehmen:

Aktien: 61.6 Mio. St.

Frei handelbar: 92.31%

Leerverk. Aktien: 18.3%

Rückkaufquote: -32.42%

Mitarbeiter: 209

Umsatz/Mitarb.: 0.11 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 137.35%

Bewertung:

KGV: -

KGV lG: -

KUV: 77.92

KBV: 5.71

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -14.37%

Gewinnmarge: -1492.9%

Operative Marge: -1225.66%

Managementeffizenz:

Gesamtkaprendite: -30.65%

Eigenkaprendite: -165.27%

>UNIQURE Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>UNIQURE Chart & Kurs - NASDAQ

>UNIQURE News

19.02.26 - 16:03	The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE (PR Newswire)
	NEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE). Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.......

19.02.26 - 02:48	NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V. (PR Newswire)
	Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE) What: Securities fraud class action lawsuit filed Class Period: September 24, 2025, and October 31, 2025 Deadline to Seek Lead......

17.02.26 - 20:01	QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"). A class......

14.02.26 - 04:12	uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC (PR Newswire)
	NEW YORK and NEW ORLEANS, Feb. 13, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a......

13.02.26 - 23:39	QURE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against uniQure N.V. (PR Newswire)
	SAN DIEGO, Feb. 13, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology......

13.02.26 - 07:24	QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, Feb. 13, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"). A class......

13.02.26 - 07:12	QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Feb. 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of......

13.02.26 - 07:12	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire)
	LOS ANGELES, Feb. 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure " or "the Company") (NASDAQ: QURE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by......

12.02.26 - 20:18	Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP (PR Newswire)
	RADNOR, Pa., Feb. 12, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or acquired uniQure......

12.02.26 - 16:06	QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to......

06.02.26 - 15:48	Uniqure-Aktie legt nach vielversprechenden Studiendaten zur Fabry-Gentherapie zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.02.26 - 13:09	uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease (GlobeNewswire EN)
	~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~...

01.02.26 - 19:57	QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Feb. 1, 2026 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure issued......

26.01.26 - 12:06	Huntington′s Advocates Press FDA to Approve UniQure′s Treatment (Bloomberg)
	Clinical trial showed it slowed progression by 75% over three years....

17.01.26 - 17:51	Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm (PR Newswire)
	RADNOR, Pa., Jan. 17, 2026 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure......

15.01.26 - 03:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Uniqure im Wert von 630483 USD (Insiderkauf)
	Gut, Robert - Aufsichtsrat - Tag der Transaktion: 2026-01-12...

13.01.26 - 02:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Uniqure im Wert von 174319 USD (Insiderkauf)
	Kaye, Jack - Aufsichtsrat - Tag der Transaktion: 2026-01-09...

09.01.26 - 19:57	uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway (Benzinga)
	uniQure N.V. (NASDAQ:QURE) shares are popping on Friday after the company said the FDA will review the data package for AMT‑130, its gene therapy for Huntington's disease, with a Type A meeting now scheduled. read more...

09.01.26 - 14:09	uniQure gains as FDA sets up meeting on gene therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 13:42	FDA-Gespräch zu Huntington-Therapie beflügelt uniQure-Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die meisten großen Politiker haben ein System wie alle großen Philosophen, das ihre Lebensführung gestimmt und sie beständig dem gleichen Ziel zustreben läßt. - Luc de Clapiers Vauvenargues

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram